On May 11, 2015, FDA conducted a public meeting on Functional GI Disorders Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of functional GI disorders on daily life and patients’ views on currently available therapies to treat the functional GI disorders, such as irritable bowel syndrome, gastroparesis, chronic persistent symptomatic gastroesophageal reflux despite standard therapeutic interventions, and chronic idiopathic constipation.
May 11, 2015
1:00 p.m. to 5:00 p.m.
FDA White Oak Campus
10903 New Hampshire Avenue
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
Enter at Building 1 to clear security
(Information about arrival to FDA's White Oak campus)
To register for this meeting, visit: Register online
Submitting comments to the public docket
In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on July 13, 2015.
- Federal Register Notice
Webinar: Background on FDA and Patient-Focused Drug Development[ARCHIVED] Functional GI Disorders PFDD Meeting Flyer(PDF - 123KB) Meeting Agenda(PDF - 133KB)
- Meeting Slides: Functional Gastrointestinal (GI) Disorders (PDF - 445KB)
Meeting Transcript(PDF - 5.8MB) The Voice of the Patient: Functional Gastrointestinal Disorders(PDF - 306KB)